Sociedad Americana de Hirudoterapia

Leech therapy for symptomatic treatment of knee osteoarthritis: results and implications of a pilot study

Andereya S, Stanzel S, Maus U, Mueller-Rath R, Mumme T, Miltner O (2006) · Alternative Therapies in Health and Medicine · n=24

Detalle de evidencia de RCTReferencia del ensayo
GRADE bajaCohorte / serie de casosCondición: Knee Osteoarthritis →
Tamaño de muestra de este ensayo en comparación con otros ensayos de Knee OsteoarthritisWang H 2018264Lauche R 2025240Lauche R 2014237Lauche R 2014237Farzali S 2025181Cui Y 2024144Andereya S 2008113Andereya S 2008113Isik M 201790Andereya S 200624
Este ensayo (destacado) por tamaño de muestra junto a otros ensayos indexados de Knee Osteoarthritis. Los ensayos más grandes generalmente tienen mayor peso estadístico.

Perfil del estudio

Diseño
single-center, open-label, controlled pilot trial (Aachen University Hospital)
Tamaño de la muestra (n)
24
Intervención
Single application of 4 Hirudo medicinalis leeches placed periarticularly around the knee
Comparador
Conventional therapy: oral NSAIDs (diclofenac 100mg/day) plus physiotherapy for 4 weeks
Punto final primario
WOMAC composite score at 4 weeks and Lequesne functional index
Resultado primario
WOMAC composite dropped 47% in leech group vs 9% in NSAID/PT group at 4 weeks (p=0.003); Lequesne index improved by 5.4 points vs 1.2 points (p<0.01)
Effect size (Cohen's d)
1.1
Duración del seguimiento
12 weeks

Hallazgos clave

  • Confirmed Michalsen 2003 signal in an independent center (Aachen vs Essen)
  • Effect emerged within 7 days and persisted through 12 weeks
  • Pilot sample (n=24) intentionally small; powered for signal detection only
  • Used 4 leeches per session — fewer than Michalsen's 4-6 — still produced robust effect
  • No washout for prior NSAID use, potentially diluting comparator arm

Limitaciones

  • Very small sample (n=24) precludes subgroup or confounder analysis
  • Open-label design — same caveats as Michalsen 2003
  • Comparator arm received both NSAIDs and physiotherapy (combined intervention)
  • 12-week follow-up too short to address durability beyond one quarter
  • No assessor blinding for WOMAC scoring

Implicaciones clínicas

Andereya 2006 served as the methodological prelude to the larger Andereya 2008 trial. Its primary value is as the first independent replication of the Michalsen 2003 signal, demonstrating that the leech-vs-NSAID effect size was not site-specific to Essen. For clinicians, this pilot strengthened the case that knee OA pain responds to leech therapy across different German academic centers and patient populations. It is rarely cited in isolation today because the 2008 follow-up (n=113) supersedes it, but it remains historically important as the bridge study.

Estudios relacionados

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.